Trial Profile
A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Pexidartinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MEDIPLEX
- 24 Jun 2020 Results of a genomic analysis using (FFPE) TGCT specimens from six clinical studies: NCT01004861, NCT02777710, NCT01217229, NCT01525602, NCT01790503 and NCT02452424 assessing CSF1 genetic alterations and rearrangements presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 26 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.